BridgeBio Pharma, Inc. (BBIO)

BridgeBio Pharma's stock has shown a substantial increase over the last year. The company reported its Fourth Quarter and Full Year 2025 earnings, with a net loss per share of $1.00, missing analyst estimates. Attruby demonstrated strong commercial momentum, with U.S. net product revenue growing 35% quarter-over-quarter in Q4 2025. The CEO engaged in significant insider selling activity in January 2026. The company entered royalty monetization deals in 2025, securing funding for Beyonttra royalties and Attruby launch. BridgeBio has received positive analyst coverage and price target increases. The company submitted a New Drug Application to the FDA for BBP-418 and presented compelling data for acoramidis (Attruby). Barclays reiterated an "Overweight" rating, noting accelerating Attruby prescriptions.

Management has indicated that they are "not seeing much first-quarter seasonality" for Attruby, suggesting that the demand for Attruby does not experience significant seasonal fluctuations. There is no specific information available to indicate demand seasonality for other products or services of BridgeBio Pharma.

BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering transformative medicines for genetic diseases and cancers with clear genetic drivers. Its major products include Attruby (acoramidis) for transthyretin amyloid cardiomyopathy, NULIBRY (Fosdenopterin) for molybdenum cofactor deficiency, low-dose infigratinib for achondroplasia and hypochondroplasia, Encaleret for Autosomal Dominant Hypocalcemia Type 1 and Chronic Hypoparathyroidism, BBP-418 for Limb-Girdle Muscular Dystrophy Type 2I, and BBP-812 for Canavan disease.

BridgeBio Pharma, Inc. is headquartered in Palo Alto, California, United States. Attruby was launched in the U.S. in 2024 and is expanding to Europe and Japan as Beyonttra in 2025 through partnerships with Bayer and Alexion.

BridgeBio Pharma's brand reputation appears to be largely positive, driven by its scientific advancements and pipeline progress. Successful long-term efficacy and safety data for Attruby and the submission of a New Drug Application for BBP-418 have positively impacted its reputation. Consistent positive analyst coverage and upgrades also contribute to a favorable image.

BridgeBio Pharma, Inc. has a mixed ownership structure comprising institutional, insider, and retail investors. As of December 2025, 421 institutional investors held 96.5% of outstanding shares. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., and Viking Global Investors Lp. The largest individual/insider shareholder is KKR Group Partnership LP.